Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Maanshan People''s Hospital,Maanshan,Anhui,China,243000[3]Cancer Hospital Chinese Academy of Medical Sciences,Beijing,Beijing,China,100000[4]Peking University People´s Hospital,Beijing,Beijing,China,100044[5]Beijing Cancer Hospital,Beijing,Beijing,China,100142[6]Fujian Medical University 2nd Affiliated Hospital,Quanzhou,Fujian,China,362001[7]The Second Hospitai. & Clinicae Medical School . Lanzhou University,Lanzhou,Gansu,China,730030[8]Cancer Hospital of Shantou University Medical College,Shantou,Guangdong,China,510000[9]Nanfang Hospital,Guangzhou,Guangzhou,China,510515[10]The fourth hospital of hebei medical university,Shijiazhuang,Hebei,China,05000[11]Tangshan People''s Hospital,Tangshan,Hebei,China,063001[12]The First Affiliated Hospital of Harbin Medical University,Harbin,Heilongjiang,China,150000[13]Henan Provincial People''S Hospital,Zhengzhou,Henan,China,450003[14]Henan Cancer Hospital Affiliated Cancer Hospital of Zhengzhou University,Zhengzhou,Henan,China,457000[15]Huazhong University of Science and Technology Tongji Medical College of Huazhong University of Science and Technology,Wuhan,Hubei,China,430000[16]The Second Xiangya Hospital of Central South University,Changsha,Hunan,China,410011[17]Baotou Cancer Hospital,Baotou,Inner Mongolia,China,014000[18]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210009[19]Liaoning Cancer Hospital & Institute,Shenyang,Liaoning,China,110000[20]The First Affiliated Hospital of China Medical University,Shenyang,Liaoning,China,110000[21]The First Affiliated Hospital of Shandong First Medical University,Jinnan,Shandong,China,250000[22]Linyi City People''s Hospital,Linyi,Shandong,China,276003[23]The Second Affiliated Hospital Of Xi''an Jiaotong University,Xi''an,Shannxi,China,710000[24]Shanxi Cancer hospital,Taiyuan,Shanxi,China,30000[25]Sichuan cancer hospital,Chengdu,Sichuan,China,610042[26]Dongyang Municipal People''s Hospital,Dongyang,Zhejiang,China,522031[27]Ningbo Medical Center Lihuili Hospital,Ningbo,Zhejiang,China,315000[28]Ningbo No.2 Hospital,Ningbo,Zhejiang,China,315010[29]Taizhou Hospital of Zhejiang Province,Taizhou,Zhejiang,China,317000
研究目的：
This is a randomized, controlled, open-label, multicenter clinical study to evaluate the efficacy and safety of carboplatin/cisplatin + etoposide + benmelstobart sequential benmelstobart combined with anlotinib versus carboplatin/cisplatin + etoposide + Tislelizumab sequential Tislelizumab in the first-line treatment of extensive stage small cell lung cancer.
